Medtronic launches first-of-its-kind adaptive deep brain stimulation (adbs) trial in parkinson's disease patients

Adapt-pd global study designed to demonstrate safety & efficacy of automated therapy which responds to brain signals in parkinson's disease patients dublin, jan. 14, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced the first...
MDT Ratings Summary
MDT Quant Ranking